1.4 Antibiotic Resistance & Antimicrobial Stewardship Principles

1.4 Antibiotic Resistance & Antimicrobial Stewardship Principles

Antimicrobial resistance (AMR) is one of the most urgent threats to global public health. In healthcare settings, excessive and inappropriate antimicrobial use drives selection pressure, resulting in multidrug-resistant organisms (MDROs) that evade conventional therapeutic regimens. Infection preventionists (IPs) collaborate with antimicrobial stewardship teams to interpret resistance mechanisms, evaluate antibiograms, and enforce prescribing controls.

1. Molecular Mechanisms of Antimicrobial Resistance

Microorganisms utilize four principal biochemical pathways to confer resistance against antimicrobial agents: enzymatic drug inactivation, target site modification, active efflux pump expression, and decreased membrane permeability.

Enzymatic Inactivation: Beta-Lactamases & Carbapenemases

Beta-lactam antibiotics (penicillins, cephalosporins, monobactams, carbapenems) kill bacteria by binding to penicillin-binding proteins (PBPs) and inhibiting peptidoglycan cell wall cross-linking. Bacteria produce beta-lactamase enzymes that hydrolyze the amide bond of the beta-lactam ring, inactivating the drug.

Target Site Modification

1. Methicillin-Resistant Staphylococcus aureus (MRSA): Mediated by acquisition of the mecA or mecC gene located on the Staphylococcal Cassette Chromosome mec (SCCmec). The mecA gene encodes Penicillin-Binding Protein 2a (PBP2a), an altered PBP with extremely low binding affinity for all beta-lactam antibiotics (penicillins, cephalosporins, carbapenems). Exception: Fifth-generation cephalosporins (ceftaroline) retain binding affinity for PBP2a.
2. Vancomycin-Resistant Enterococcus (VRE): Primarily seen in Enterococcus faecium. Mediated by the vanA or vanB gene clusters, which alter the terminal cell wall peptidoglycan precursor from D-alanyl-D-alanine to D-alanyl-D-lactate (or D-alanyl-D-serine). This structural modification reduces vancomycin binding affinity by more than 1,000-fold.
3. Fluoroquinolone Resistance: Point mutations in chromosomal genes encoding DNA gyrase (gyrA) and topoisomerase IV (parC) alter target binding, rendering fluoroquinolones (ciprofloxacin, levofloxacin) ineffective in Gram-negative and Gram-positive pathogens.

Efflux Pumps & Outer Membrane Permeability

• Efflux Pumps: Energy-dependent transmembrane pumps actively transport antibiotics out of the bacterial cytoplasm. Overexpression of the MexAB-OprM efflux system in Pseudomonas aeruginosa confers resistance to fluoroquinolones, beta-lactams, and aminoglycosides.
• Porin Loss: Gram-negative bacteria reduce expression or alter channel architecture of outer membrane porin proteins (e.g., OprD loss in P. aeruginosa), blocking carbapenem entry into the periplasmic space.

2. CDC Core Elements of Antimicrobial Stewardship

The CDC outlines seven Core Elements for hospital Antimicrobial Stewardship Programs (ASPs) designed to optimize clinical outcomes while minimizing unintended consequences (MDRO emergence, C. difficile toxicity, financial costs):

1. Leadership Commitment: Allocating financial, human, and information technology resources.
2. Accountability: Appointing a single physician leader responsible for program outcomes.
3. Pharmacy Expertise: Appointing a co-lead clinical pharmacist dedicated to stewardship.
4. Action: Implementing key interventions, such as prospective audit and feedback or pre-authorization.
5. Tracking: Monitoring prescribing patterns, antibiotic consumption (Days of Therapy [DOT] per 1,000 patient-days), and resistance trends.
6. Reporting: Regularly sharing antibiotic usage and resistance data with clinicians and leadership.
7. Education: Providing ongoing education to prescribers, pharmacists, and nurses on stewardship practices.

Core Stewardship Interventions

• Prospective Audit and Feedback (PAF): The stewardship team reviews active antimicrobial therapy after 48–72 hours of administration and provides real-time, evidence-based recommendations to prescribers regarding dose optimization, de-escalation, or discontinuation.
• Formulary Restriction & Pre-Authorization: Restricting high-risk, broad-spectrum, or expensive agents (e.g., daptomycin, linezolid, carbapenems, novel beta-lactamase inhibitor combinations) requiring Infectious Disease approval prior to pharmacy dispensing.
• Diagnostic Stewardship: Guidelines ensuring appropriate specimen collection (e.g., restricting urine cultures in catheterized patients without symptoms) to prevent misinterpretation and unnecessary treatment.

3. Cumulative Antibiograms: Construction & Interpretation

A cumulative antibiogram is an annual institutional report summarizing the percentage of target bacterial isolates susceptible to evaluated antimicrobial agents.

CLSI M39 Guidelines for Construction

Clinical and Laboratory Standards Institute (CLSI) M39 standards mandate strict rules for antibiogram compilation:

• First Isolate Only: Include only the first isolate per patient per species collected during the 1-year analysis period, regardless of body site or susceptibility profile. Excluding duplicate isolates prevents artificial inflation of resistance rates from chronically infected patients.
• Minimum Isolate Threshold: Include only species with at least 30 tested isolates per reporting period. Antibiograms based on fewer than 30 isolates lack statistical reliability and can distort susceptibility estimates.
• Separate Inpatient vs. Outpatient Data: Sub-analyses should differentiate intensive care units (ICUs) from general wards and outpatient clinics due to varying baseline resistance rates.

Clinical & Infection Control Application

Clinicians utilize antibiograms to select optimal empirical antimicrobial therapy before definitive culture and susceptibility results return. IPs monitor annual antibiogram trends to evaluate the spread of MDROs across departments, assess the impact of stewardship interventions, and detect emerging local resistance mechanisms.